Effect of increasing ratio of estrogen:androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP

Prostate

Volumn 66, Issue 1, 2006, Pages 105-114

  King, Keith J ^a   Nicholson, Helen D ^a   Assinder, Stephen J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Androgen; BPH; Cell proliferation; Estrogen; LNCaP; Prostate

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; COMPLEMENTARY DNA; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; RNA;

AGING; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

CELL DIVISION; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; DNA PRIMERS; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; MALE; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 29344465951     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20327     Document Type: Article

References (64)

1. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-409.
2. Novelli G, Margiotti K, Sangiuolo F, Reichardt JK. Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2001;2:65-72.
3. Price D. Comparative aspects of development and structure in the prostate. Natl Cancer Inst Monogr 1963;12:1-27.
4. McNeal JE. Normal and pathologic anatomy of prostate. Urology [Suppl] 1981;27:11-16.
5. Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF. Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. Prog Clin Biol Res 1980;37:67-84.
6. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
7. Schwab TS, Stewart T, Lehr J, Pienta KJ, Rhim JS, Macoska JA. Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures. Prostate 2000;44:164-171.
8. Berry SJ, Coffey DS, Walsh PS, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
9. Levine AC, Kirschenbaum A, Gabrilove JL. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. Mt Sinai J Med 1997;64:20-25.
10. Huggins C, Stevens RE, Hodges CV. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1991;43:209-223.
11. Irvine RA, Yu MC, Ross RK, Coetzee GA. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995;55:1937-1940.
12. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MAS, Narod SA. V89L polymorphism of type-2,5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001;57:199-205.
13. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93:5925-5930.
14. Farnsworth WE. Estrogen in the etiopathogenesis of BPH. Prostate 1999;38:263-274.
15. Moore RJ, Gazak JM, Wilson JD. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17 beta-estradiol. J Clin Invest 1979;63:351-357.
16. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976;57:1093-1097.
17. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-1933.
18. Habenicht UF, Schwarz K, Neumann F, el Etreby MF. Induction of estrogen-related hyperplastic changes in the prostate of the cynomolgus monkey (Macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-1,4-diene-3,17-dione. Prostate 1987;11:313-326.
19. Winter ML, Bosland MC, Wade DR, Falvo RE, Nagamani M, Liehr JG. Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5 alpha-dihydrotestosterone and 17beta-estradiol. Prostate 1995;26:325-333.
20. Cancel-Tassin G, Latil A, Rousseau F, Mangin P, Bottius E, Escary JL, Berthon P, Cussenot O. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol 2003;44:487-490.
21. Shibata Y, Ito K, Suzuki K, Nakano K, Fukabori Y, Suzuki R, Kawabe Y, Honma S, Yamanaka H. Changes in the endocrine environment of the human prostate transition zone with aging: Simultaneous quantitative analysis of prostatic sex steroids and comparison with human prostatic histological composition. Prostate 2000;42:45-55.
22. Ho SM. Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cellular Biochem 2004;91:495-503.
23. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-353.
24. Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT. Body size and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2000;9:1335-1341.
25. Hubbard JS, Rohrmann S, Landis PK, Metter EJ, Muller DC, Andres R, Carter HB, Platz EA. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology 2004;63:253-258.
26. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-1244.
27. Goossens K, Deboel L, Swinnen JV, De Gendt K, Rombauts W, Verhoeven G. Effects and characterization of paracrine factors produced by human prostate stromal cells in bioassays using rat Sertoli cells, LNCaP tumor cells, and cultured prostate epithelial cells. Prostate 2001;48:104-117.
28. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-851.
29. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr-Relat Cancers 2005;12:19-47.
30. Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Comm 1991;3:207-212.
31. Bayne CW, Donnelly F, Chapman K, Bollina P, Buck C, Habib F. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5 alpha-reductase. J Clin Endocrinol Metab 1998;83:206-213.
32. Sokal RR, Rohlf FJ. Biometry, 2nd edition. New York: Freeman and Co. 1981.
33. Minamiguchi K, Kawada M, Someno T, Ishizuka M. Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness. Biochem Biophys Res Commun 2003;306:629-636.
34. Collins AT, Zhiming B, Gilmore K, Neal DE. Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: Oestrogen regulation of the androgen receptor. J Endocrinol 1994;143:269-277.
35. Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, Hittmair A, Culig Z, Bartsch G, Klocker H. Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997;30:117-129.
36. Planz B, Wang Q, Kirley SD, Lin CW, McDougal WS. Androgen responsiveness of stromal cells of the human prostate: Regulation of cell proliferation and keratinocyte growth factor by androgen. J Urol 1998;160:1850-1855.
37. Nakano K, Fukabori Y, Itoh N, Lu W, Kan M, McKeehan WL, Yamanaka H. Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10. Endocr J 1999;46:405-413.
38. Janssen M, Albrecht M, Moschler O, Renneberg H, Fritz B, Aumuller G, Konrad L. Cell lineage characteristics of human prostatic stromal cells cultured in vitro. Prostate 2000;43:20-30.
39. Isaacs JT, Brendler CB, Walsh PC. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate. J Clin Endocrinol Metab 1983;56:139-146.
40. Yeh S, Miyamoto H, Shima H, Chang C. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 1998;95:5527-5532.
41. Berthon P, Waller AS, Villette JM, London L, Cussenot O, Maitland NJ. Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int J Cancer 1997;10:910-916.
42. Schuurmans AL, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988;12:55-63.
43. Castagnetta LA, Miceli MD, Sorci CM, Pfeffer U, Farruggio R, Oliveri G, Calabro M, Carruba G. Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 1995;136:2309-2319.
44. Negri-Cesi P, Motta M. Androgen metabolism in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 1994;51:89-96.
45. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
46. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-2864.
47. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992;41:665-669.
48. Stathopoulos EN, Dambaki C, Kampa M, Theodoropoulos PA, Anezinis P, Delakas D, Delides GS, Castanas E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC Clin Pathol 2003;30:1.
49. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136:796-803.
50. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996;93:15152-15157.
51. Maggiolini M, Vivacqua A, Carpino A, Bonofiglio D, Fasanella G, Salerno M, Picard D, Ando S. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol 2002;62:1027-1035.
52. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991;51:5165-5170.
53. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B, Panaye G. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 2000;73:237-249.
54. Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: Experimental paradox or clinical reality. Eur Urol 2004;46:285-294.
55. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
56. Chang SM, Chung LWK. Interaction between prostatic fibroblasts and epithelial cells in culture: Role of androgen. Endocrinology 1989;125:2719-2727.
57. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: In vitro and in vivo characterization. Prostate 2003;55:206-218.
58. Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS, Taylor J, Lubahn DB, Cunha GR. Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium. Proc Natl Acad Sci USA 1997;94:6535-6540.
59. Sherwood ER, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 1992;130:2955-2963.
60. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 1994;79:1410-1415.
61. Cunha GR. Growth factors as mediators of androgen action during male urogenital development. Prostate Suppl 1996;6:22-25.
62. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, French FS, Wilson EM. The human androgen receptor: Complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Molec Endocr 1988;2:1265-1275.
63. Schubert EL, Lee MK, Newman B, King MC. Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 1999;7:21-27.
64. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human estrogen receptor beta (hEbeta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998;243:122-126.